| Literature DB >> 34223080 |
Tsegaye Sewunet1,2, Daniel Asrat1, Yimtubezinash Woldeamanuel1, Sofia Ny3, Fredrik Westerlund4, Abraham Aseffa5, Christian G Giske2,6.
Abstract
BACKGROUND: Genomic epidemiology of antibiotic resistance is not sufficiently studied in low-income countries.Entities:
Year: 2021 PMID: 34223080 PMCID: PMC8210115 DOI: 10.1093/jacamr/dlab001
Source DB: PubMed Journal: JAC Antimicrob Resist ISSN: 2632-1823
Figure 1.Flow chart showing prevalence of ESBL-KP strains at different units of the hospital. OPD, outpatient department.
List of AMR genes and their prevalence in K. pneumoniae strains isolated at Jimma Medical Center, Ethiopia
| Serial no. | Class of antimicrobial | Gene description and resistance mechanism | Genes detected | Prevalence | ||
|---|---|---|---|---|---|---|
| sub-class genes | putative mechanisms | drugs targeted | ||||
| 1 | Aminoglycosides | acetylation genes | acetyl transferase | aminoglycosides |
| 18 (16.5%) |
| acetyl transferase | aminoglycosides |
| 1 (0.9%) | |||
| acetyl transferase | aminoglycosides and fluoroquinolones |
|
| |||
| acetyl transferase | aminoglycosides |
| 2 (1.8%) | |||
| acetyl transferase | aminoglycosides |
| 2 (1.8%) | |||
| adenylation | adenyl transferase | aminoglycosides |
| 4 (3.6%) | ||
| tetracycline efflux | aminoglycosides |
| 14 (12.8%) | |||
| adenyl transferase | aminoglycosides |
| 1 (0.9%) | |||
| adenyl transferase | aminoglycosides |
| 3 (2.7%) | |||
| streptomycin | streptomycin phosphotransferase | aminoglycosides |
|
| ||
| streptomycin phosphotransferase | aminoglycosides |
|
| |||
| phosphorylation | aminoglycosides phosphotransferase | aminoglycosides |
| 10 (9.2%) | ||
| 2 | β-lactams |
| β-lactamase | cephamycins |
| 1 (0.9%) |
| β-lactamase | cephamycins |
| 2 (1.8%) | |||
|
| ESBL | aminopenicillins and cephalosporins |
| 4 (3.6%) | ||
| ESBL | aminopenicillins and cephalosporins |
| 2 (1.8%) | |||
| ESBL | aminopenicillins and cephalosporins |
|
| |||
| ESBL | aminopenicillins and cephalosporins |
| 1 (0.9%) | |||
| ESBL | aminopenicillins and cephalosporins |
| 1 (0.9%) | |||
|
| β-lactamase | aminopenicillins |
| 38 (34.8%) | ||
| ESBL | aminopenicillins and cephalosporins |
| 12 (11.0%) | |||
|
| β-lactamase | aminopenicillins |
| 76 (69.7%) | ||
| β-lactamase | aminopenicillins |
| 2 (1.8%) | |||
| β-lactamase | aminopenicillins |
| 14 (12.8%) | |||
|
| β-lactamase | aminopenicillins |
| 23 (21.1%) | ||
| β-lactamase | aminopenicillins |
| 3 (2.7%) | |||
| ESBL | aminopenicillins and cephalosporins |
| 4 (3.6%) | |||
| β-lactamase | aminopenicillins |
| 7 (6.3%) | |||
| 3 | Carbapenem | carbapenemase | metallo-β-lactamase | aminopenicillins, cephalosporins and carbapenems |
| 1 (0.9%) |
| 4 | Phenicols | acetyl transferase | chloramphenicol |
|
| |
| acetyl transferase | chloramphenicol |
| 6 (5.4%) | |||
| 5 | Trimethoprim | dihydrofolate reductase | sulfamethoxazole/co-trimoxazole |
| 5 (4.5%) | |
| dihydrofolate reductase | sulfamethoxazole/co-trimoxazole |
| 10 (9.2%) | |||
| dihydrofolate reductase | sulfamethoxazole/co-trimoxazole |
| 2 (1.8%) | |||
| dihydrofolate reductase | sulfamethoxazole/co-trimoxazole |
|
| |||
| dihydrofolate reductase | sulfamethoxazole/co-trimoxazole |
| 1 (0.9%) | |||
| dihydrofolate reductase | sulfamethoxazole/co-trimoxazole |
| 14 (12.8%) | |||
| 6 | Fosfomycin | Glutathione transferase | fosfomycin |
|
| |
| 7 | Macrolides | macrolide phosphotransferase | chloramphenicol |
|
| |
| 8 | Quinolones | QepA | efflux pump | fluoroquinolones |
| 1 (0.9%) |
| QnrB | plasmid mediated quinolone resistance | fluoroquinolones |
| 13 (11.9%) | ||
| QnrS | plasmid mediated quinolone resistance | fluoroquinolones |
| 18 (16.5%) | ||
| 8 | Tetracycline | Tet | efflux pump | tetracyclines |
|
|
| efflux pump | tetracyclines |
| 4 (3.6%) | |||
| efflux pump | tetracyclines |
| 20 (18.3%) | |||
| 10 | Sulphonamides | Sul | dihydropteroate synthase | sulphonamides and co-trimoxazole |
|
|
| dihydropteroate synthase | sulphonamides and co-trimoxazole |
| 66 (60.5%) | |||
| 11 | Rifampicin | ARR | ADP-ribosylation catalysing enzyme | rifampicin |
| 8 (7.3%) |
| ADP-ribosylation catalysing enzyme | rifampicin |
|
| |||
Bold indicates the most prevalent gene for a particular class of antimicrobial.
Prevalence of MDR, type of antimicrobial and the combined resistance of the K. pneumoniae strains
| Strains, | Antibiogram of ESBL strains of | Number of drugs | Number of antimicrobial classes |
|---|---|---|---|
| 8 (7%) |
| 3 | 2 |
| CTX-CAZ-GEN (12.5%) | |||
| CTX-CAZ-GEN (25%) | |||
| 19 (17%) |
| 4 | 3 |
| CTX-CAZ-CIP-SXT (26.3%) | |||
| CTX-CAZ-MEM-GEN (5.2%) | |||
| CTX-CAZ-SXT-MEM-GEN (10.5%) | 5 | ||
| 40 (36%) | CTX-CIP-SXT-GEN (2.5%) | 4 | 4 |
|
| 5 | ||
| CTX-CAZ-TZP-SXT-GEN (32.5%) | |||
| CTX-CAZ-CIP-SXT-MEM (12.5%) | |||
| CTX-CAZ-SXT-MEM-GEN (10%) | |||
| CTX-CAZ-TZP-CIP-SXT (5%) | |||
| CTX-CAZ-TZP-CIP-AMK (2.5%) | |||
| 26 (24%) | CTX-TZP-CIP-SXT-GEN (3.8%) | 5 | 5 |
|
| 6 | ||
| CTX-CAZ-CIP-SXT-MEM-GEN (19.2%) | |||
| CTX-CAZ-TZP-SXT-MEM-GEN (3.8%) | |||
| 17 (16%) |
| 7 | 6 |
| CTX-CAZ-TZP-CIP-SXT-ETP-MEM-GEN-AMK (5.8%) | 9 |
CTX, cefotaxime; TZP, piperacillin/tazobactam; CIP, ciprofloxacin, CAZ, ceftazidime, AMK, amikacin; SXT, trimethoprim/sulfamethoxazole; ETP, ertapenem; MEM, meropenem; IPM, imipenem; GEN, gentamicin.
Bold indicates the most prevalent resistance patterns.
Figure 2.Clusters of epidemic clones isolated from the surgical unit, paediatric unit, ICU and medical unit of the hospital.